Another cathepsin K inhibitor, odanacatib, has been tested in mouse models of AP and is reported to reduce bone resorption by inhibiting osteoclast activation and differentiation [52] (Figure 2(b-2)). Here, CTSK is linked to alkaline phosphatase measurement.